CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarterFirst and only cell therapy clinically shown to significantly extend overall survival versus standard therapies in multiple myeloma patients as early as second line; presented CARTITUDE-4 three-year follow-up data at the International Myeloma Society Annual MeetingInitiated commercial production at Obelisc facility in Ghent, BelgiumLaunched in Switzerland during the third quarter and recently received label expansion into third-line plus settings for multiple myeloma patients Received China's NMPA appro

SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program. Investors and other interested parties may join the live webcast through this weblink or by visiting Legend Biotech's

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg

SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review third-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approxi

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn

The collaboration between Multiply Labs and Legend Biotech will focus on applying advanced robotic technology to the manufacturing of cell therapy platforms Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced the launch of its collaboration with Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in the cell therapy space. This initiative will be focused on automating cell therapy manufacturing, leveraging Multiply Labs' unique approach which consists of robotic systems that can operate a wide variety of instruments already deployed in the cell and gene therapy industry. This c

PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (NASDAQ:LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research and manufacturing services, today announced that they have received approval from the China National Medical Products Administration (NMPA) for its cell therapy product, ciltacabtagene autoleucel (cilta-cel). This groundbreaking treatment is approved for use in adult patients with relapsed or refractory multiple myeloma (MM) who have previously undergone at least three prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent. The approval of cilt

SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend's website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH  Legend Biotech is a global biotechnology company dedicated t

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myelomaCARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 studyCash and cash equivalents, deposits and short-term investments of $1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profit SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a globa

SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9. "We are pleased to welcome Dr. Salovey to the Legend Board," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Dr. Salovey's deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic dec

Redburn Atlantic initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $86.00

Truist initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $88.00

H.C. Wainwright reiterated coverage of Legend Biotech with a rating of Buy and set a new price target of $73.00 from $86.00 previously

Deutsche Bank initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $60.00

Scotiabank upgraded Legend Biotech from Sector Perform to Sector Outperform and set a new price target of $65.00

Cantor Fitzgerald initiated coverage of Legend Biotech with a rating of Overweight and set a new price target of $82.00

Raymond James initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $86.00

Scotiabank initiated coverage of Legend Biotech with a rating of Sector Perform

Goldman initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $90.09

William Blair initiated coverage of Legend Biotech with a rating of Mkt Perform and set a new price target of $64.00

S-8 - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

6-K - Legend Biotech Corp (0001801198) (Filer)

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarterFirst and only cell therapy clinically shown to significantly extend overall survival versus standard therapies in multiple myeloma patients as early as second line; presented CARTITUDE-4 three-year follow-up data at the International Myeloma Society Annual MeetingInitiated commercial production at Obelisc facility in Ghent, BelgiumLaunched in Switzerland during the third quarter and recently received label expansion into third-line plus settings for multiple myeloma patients Received China's NMPA appro

SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review third-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approxi

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myelomaCARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 studyCash and cash equivalents, deposits and short-term investments of $1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profit SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a globa

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024. For the six-months ended June 30, 2024, Legend Biotech expects to record an adjusted net loss for the period of approximately $94.7 million to $109.7 million. See "Use of Non-IFRS Financial Measures" below for a reconciliation of net loss to adjusted net loss for the first six months of the year. This preliminary estimated data should not be considered as a substitute for the full unaudited financial results for the six-months ended June 30, 2024, w

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately tw

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma Legend and Johnson & Johnson enter into Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation On April 5, Legend Biotech earned a milestone payment of $45 million in connection with FDA's approval of CARVYKTI's label expansion to treat 2L+ MM, in accordance with the Janssen Agreement* Cash and cash equivalents, deposits, and short-term investments of $1.3 billion, as of March 31, 2024, which

Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes. ABOUT LEGEND BI

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $159 million and $500 million for the fourth quarter and full year 2023, respectively CHMP recommended CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma. FDA ODAC to meet on March 15 to review data from the CARTITUDE-4 study supporting the use of cilta-cel in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma On January 3, 2024, Legend received a $100 million upfront payment in connection with its global license agreement with Novartis Pharma AG to develop, manufactur

Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results. During the webcast and conference call, executive members will provide an overview of Legend Biotech's performance for the quarter and the fiscal year. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section

Legend Biotech Corporation (the "Company" or Legend Biotech), through its wholly owned subsidiary, Legend Biotech Ireland Limited, entered into an exclusive, global license agreement with Novartis Pharma AG. The Company granted Novartis the rights to develop, manufacture and commercialize LB2102 (NCT05680922) and other potential chimeric antigen receptor T-cell (CAR-T) therapies selectively targeting Delta-like ligand 3 (DLL3).1 Subject to closing, Novartis has agreed to pay the Company an upfront payment of $100 million after closing the transaction and up to $1.01 billion in milestone payments, as well as tiered royalties on net sales CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) g

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had discussed plans to split its digital streaming and studio businesses from its legacy television networks. MicroStrategy Inc.’s (NASDAQ:MSTR) stock gained 16.74% last week amid a rise in Bitcoin’s price. D.R. Horton, Inc. (NYSE:DHI) shares surged 12.91% after the company reported better-than-expected Q3 financial results and revised FY24 guidance. The company also authorized a new $4 billion share repurchase. Few analysts raised the price forecasts on the stock. Coinbase Global Inc.’s

Scotiabank analyst George Farmer maintains Legend Biotech (NASDAQ:LEGN) with a Sector Outperform and raises the price target from $65 to $70.

U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-than-expected quarterly EPS and revenues. Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from Benzinga Pro. Cintas shares gained 5.3% to $758.25 on Thursday. Here are some other big stocks recording gains in today’s session. Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares gained 47.6% to $37.29 after the company and Darde

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price target.

In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 10 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 3 0 0 0 2M Ago 4 0 0 0 0 3M Ago 3 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $78.93, a high estimate of $90.00, and a low estimate of $60.00. Highlighting a 2.56% decrease, the current average

TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price target from $71 to $67.

BMO Capital analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $90 price target.

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price target.

On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating Carvykti (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. In simple words, the study compared Carvykti, a treatment for multiple myeloma, to other standard therapies. This research focused on patients whose multiple myeloma has returned or did not respond to initial treatments, after only one previous treatment. The interim analysis showed a s